What It Is & Why It's in Vaccines

Aluminum hydroxide is an aluminum salt used as an adjuvant in inactivated and subunit vaccines. Adjuvants are substances added to vaccines to enhance the body's immune response to the antigen, allowing smaller or fewer doses to achieve protective immunity.

Aluminum hydroxide (and related aluminum salts including aluminum phosphate and aluminum hydroxyphosphate sulfate) are the most widely used vaccine adjuvants globally, in use since the 1930s. They work by creating a depot effect at the injection site — slowing antigen release — and by activating the NLRP3 inflammasome, which stimulates a stronger and more durable antibody response.

Dose-in-Context

Per-Dose Quantity

0.125–0.85 mg aluminum per 0.5 mL dose, depending on product (FDA limit: ≤0.85 mg/dose for individual products, 21 CFR 610.15)

Reference Comparison

Infants receive approximately 0.01–0.04 mg/kg/day of aluminum from breast milk, and approximately 0.04–0.4 mg/kg/day from soy-based formula (higher than breast milk). The total aluminum exposure from the complete US infant vaccine schedule (birth–6 months) is approximately 4.2 mg, or roughly 0.13 mg/kg/month averaged over the period — comparable to or lower than dietary aluminum intake from infant formula over the same timeframe.

Source: Mitkus RJ, King DB, Hess MA, Forshee RA, Walderhaug MO. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Vaccine. 2011;29(51):9538-9543. doi:10.1016/j.vaccine.2011.09.124

Route-of-Administration Note

Aluminum pharmacokinetics differ between injected (intramuscular/subcutaneous) and oral routes. The Mitkus et al. (2011) model specifically accounts for these differences — injected aluminum is absorbed into systemic circulation over weeks, and renal clearance is the primary elimination pathway. The model found that vaccine-derived aluminum exposure contributes a small fraction of total infant aluminum body burden compared to dietary sources, even at regulatory maximums.

Documented Adverse Effects

Established / Labeled Risk MODERATE

Local injection-site reactions (pain, erythema, swelling, nodule formation) are more common with aluminum-adjuvanted vaccines than with non-adjuvanted comparators — this is a well-established, immunologically expected effect of the adjuvant mechanism itself, not an unexpected adverse reaction.

Established / Labeled Risk MODERATE

Persistent subcutaneous nodules (granulomas) at the injection site have been documented, particularly after subcutaneous (rather than intramuscular) administration. These are typically benign and self-resolving.

Established / Labeled Risk MODERATE

Contact hypersensitivity to aluminum (positive patch test, persistent itching nodules) has been documented in a small subset of children following aluminum-adsorbed vaccines. The estimated incidence is approximately 0.2–1% of vaccinated children, with wide variation by study population and diagnostic criteria.

Studied & Not Supported STRONG

The hypothesis that vaccine aluminum contributes to neurodevelopmental disorders (including autism spectrum disorder) has been extensively investigated in multiple large epidemiological studies and systematic reviews. The Institute of Medicine (now National Academy of Medicine) reviews (2004, 2012) and subsequent large-scale epidemiological studies have not found evidence of a causal association between vaccine aluminum exposure and neurodevelopmental outcomes.

Limited Data / Open Question PRELIMINARY

Macrophagic myofasciitis (MMF) — a rare histopathological finding of aluminum-containing macrophages at previous intramuscular vaccination sites, described primarily in French case series. The clinical significance of this histological finding (as distinct from localized injection-site reactions) remains debated, with no clear dose-response relationship established and significant variation in diagnostic criteria across centers. Well-controlled prospective studies with standardized diagnostic criteria are lacking.

Vaccines Containing Aluminum Hydroxide

Hepatitis B — Engerix-B (GlaxoSmithKline Biologicals)

DTaP/Tdap — Infanrix (GlaxoSmithKline Biologicals)

Meningococcal — Bexsero (GlaxoSmithKline Biologicals)

Hepatitis A — Havrix (GlaxoSmithKline Biologicals)

Japanese Encephalitis — Ixiaro (Valneva Austria GmbH)

ⓘ Methodology Disclaimer: Ingredient lists are sourced from official FDA-approved package inserts for the specific branded products named on each vaccine page. Formulations can change between manufacturing lots and over time — always verify against the current package insert before making a clinical decision. The presence of a substance in a vaccine does not by itself indicate harm; toxicology is dose-, route-, and context-dependent. Comparisons to reference exposure levels are provided with their sources where available, and are approximate — see the cited source for full methodology.